BACKGROUND: Platelet activation by platelet activating factor (PAF) seems to be involved in the inflammatory process in asthma and may serve as a possible target for the antiinflammatory drug nedocromil sodium, which is known to inhibit cell activation by different stimuli. METHODS: We investigated the effect and the mode of action of nedocromil sodium on platelet activation by PAF. In a set of healthy volunteers (n = 45) we investigated seven different parameters of platelet activation by PAF, thrombin, and Ca(2+)-ionophore. RESULTS: Nedocromil sodium inhibited: (1) PAF-induced "shape change" reaction up to 78% (50% inhibitory concentration [IC50]: 3 x 10(-9) mol/L), thrombin-mediated "shape change" up to 80% (IC50 2 x 10(-8) mol/L), but not the Ca(2+)-ionophore-dependent reaction, (2) platelet aggregation by PAF up to 85% (IC50 2 x 10(-9) mol/L); (3) release of thromboxane B2 up to 82% (IC50 5 x 10(-9) mol/L); (4) formation of inositol 1,4,5-triphosphate by PAF (IC50 3 x 10(-7) mol/L), by thrombin (IC50 1 x 10(-7) mol/L), but not by Ca2+ ionophore; (5) increase of intracellular free calcium (IC50 4 x 10(-7) mol/L); (6) formation of diacylglycerol (IC50 9 x 10(-9) mol/L), and (7) translocation of protein kinase C (IC50 1 x 10(-7) mol/L). CONCLUSIONS: In the concentration range of the IC50 values found in these experiments, nedocromil sodium reduced PAF binding to platelets by only 10% to 20%, such that this interference cannot explain the observed effects of the compound. Inhibition of receptor-mediated platelet activation at an early stage in the signal transduction pathway, and without effect on Ca(2+)-ionophore-induced platelet activation, suggests an action of nedocromil sodium at the level of the cell membrane.
BACKGROUND: Platelet activation by platelet activating factor (PAF) seems to be involved in the inflammatory process in asthma and may serve as a possible target for the antiinflammatory drug nedocromil sodium, which is known to inhibit cell activation by different stimuli. METHODS: We investigated the effect and the mode of action of nedocromil sodium on platelet activation by PAF. In a set of healthy volunteers (n = 45) we investigated seven different parameters of platelet activation by PAF, thrombin, and Ca(2+)-ionophore. RESULTS:Nedocromil sodium inhibited: (1) PAF-induced "shape change" reaction up to 78% (50% inhibitory concentration [IC50]: 3 x 10(-9) mol/L), thrombin-mediated "shape change" up to 80% (IC50 2 x 10(-8) mol/L), but not the Ca(2+)-ionophore-dependent reaction, (2) platelet aggregation by PAF up to 85% (IC50 2 x 10(-9) mol/L); (3) release of thromboxane B2 up to 82% (IC50 5 x 10(-9) mol/L); (4) formation of inositol 1,4,5-triphosphate by PAF (IC50 3 x 10(-7) mol/L), by thrombin (IC50 1 x 10(-7) mol/L), but not by Ca2+ ionophore; (5) increase of intracellular free calcium (IC50 4 x 10(-7) mol/L); (6) formation of diacylglycerol (IC50 9 x 10(-9) mol/L), and (7) translocation of protein kinase C (IC50 1 x 10(-7) mol/L). CONCLUSIONS: In the concentration range of the IC50 values found in these experiments, nedocromil sodium reduced PAF binding to platelets by only 10% to 20%, such that this interference cannot explain the observed effects of the compound. Inhibition of receptor-mediated platelet activation at an early stage in the signal transduction pathway, and without effect on Ca(2+)-ionophore-induced platelet activation, suggests an action of nedocromil sodium at the level of the cell membrane.